ADVANCING THE PROMISE OF INNOVATION TO IMPROVE LIVES
Oblenio Bio is an emerging biotechnology company that is dedicated to solving the toughest treatment challenges across a broad range of autoimmune diseases. The company is focused on achieving the significant potential of T-cell engagers as a novel therapeutic approach that addresses underlying disease pathophysiology and achieves immune reset.
An Aditum Bio company, Oblenio Bio was formed in November 2024 following the exclusive option to license LBL-051, a first-in-class T-cell engager antibody that targets both CD19 and BCMA in autoimmune disorders.
OUR APPROACH
CD19/BCMA Dual Targeting
We are at the forefront of applying novel science in T-cell engager antibodies to develop a potentially robust and durable therapeutic approach for autoimmune diseases.
LBL-051 is the most advanced tri-specific T-cell engager in development that targets both CD19 and BCMA. The dual targeting functionality of LBL-051 sets it apart, enabling it to deplete pathological B-cell populations that are implicated in a wide spectrum of autoimmune diseases.
Resetting the Immune System
LBL-051 is engineered to elevate the demonstrated clinical potential of CD19- and BCMA-targeted therapies to solve difficult treatment challenges in autoimmune diseases. As a CD19 and BCMA dual targeting T-cell engager, LBL-051 is designed to deplete the entire lineage of pathological B cells and achieve immune reset – potentially delivering superior efficacy and durability compared to single targeting of either CD19 or BCMA alone.
OUR FOCUS
Raising the Bar on T-Cell Engagers
Our team is focused on unlocking the full potential of CD19 and BCMA dual targeting as a paradigm-shifting treatment approach across a broad array of autoimmune diseases.
OUR TEAM
LEADERSHIP
Meet the leadership team spearheading our exciting mission to transform the autoimmune treatment paradigm.
BOARD OF DIRECTORS
